New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT07218003

ENROLLING_BY_INVITATION Disease control Sponsor: Rondo Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors or slows their growth. About 149 participants will receive weekly infusions of RNDO-564, with some also getting pembrolizumab every three weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma bladder transitional cell carcinoma cancer cervical cancer esophageal squamous cell carcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma neoplasm non-small cell lung carcinoma triple-negative breast carcinoma Urinary Bladder Neoplasms urothelial carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER CERVICAL CANCER ESOPHAGEAL SQUAMOUS CELL CANCER GASTRIC CANCER GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA HEAD AND NECK SQUAMOUS CELL CANCER NON-SMALL CELL LUNG CANCER SOLID TUMORS (PHASE 1) TRIPLE-NEGATIVE BREAST CANCER (TNBC) UROTHELIAL CARCINOMA BLADDER

Contacts and locations

Locations

Carolina Biooncology

Huntersville, North Carolina, 28078, United States
Carolina Urologic Research Center

Myrtle Beach, South Carolina, 29572, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
START Center for Cancer Research

San Antonio, Texas, 78229, United States
START Midwest

Grand Rapids, Michigan, 49546, United States
START Mountain Region

West Valley City, Utah, 84119, United States
Sarah Cannon Research Institute, LLD

Nashville, Tennessee, 37203, United States
UCSF Medical Center

San Francisco, California, 94143, United States
Yale Cancer Center

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.